{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:59:44Z","timestamp":1791244784069,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013885","name":"Kementerian Kesihatan Malaysia","doi-asserted-by":"publisher","award":["91000050"],"award-info":[{"award-number":["91000050"]}],"id":[{"id":"10.13039\/501100013885","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-60963-3","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:17:40Z","timestamp":1783354660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and sociodemographic characteristics of metabolic dysfunction-associated fatty liver subtypes in Malaysia"],"prefix":"10.1038","volume":"16","author":[{"given":"Kim Sui","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah Kheong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Fadhli","family":"Mohd Yusoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feisul","family":"Mustapha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurain","family":"Mohd Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor Ani","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"60963_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73, 202\u2013209 (2020).","journal-title":"J. Hepatol."},{"key":"60963_CR2","doi-asserted-by":"crossref","unstructured":"Chan, K. E. et al. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals. The Journal of Clinical Endocrinology & Metabolism 107, 2691\u20132700, (2022). https:\/\/doi.org\/10.1210\/clinem\/dgac321%JThe Journal of Clinical Endocrinology & Metabolism.","DOI":"10.1210\/clinem\/dgac321"},{"key":"60963_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatol. (Baltimore Md). 77, 1335\u20131347. https:\/\/doi.org\/10.1097\/hep.0000000000000004 (2023).","journal-title":"Hepatol. (Baltimore Md)"},{"key":"60963_CR4","doi-asserted-by":"publisher","unstructured":"Wan, K. S. et al. Prevalence and factors associated with metabolic dysfunction-associated fatty liver disease in a multiethnic Asian country. Scientific reports 16, (1922). https:\/\/doi.org\/10.1038\/s41598-025-31737-0 (2026).","DOI":"10.1038\/s41598-025-31737-0"},{"key":"60963_CR5","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1007\/s12072-022-10407-7","volume":"16","author":"H Lee","year":"2022","unstructured":"Lee, H., Lim, T. S., Kim, S. U. & Kim, H. C. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population. Hep. Intl. 16, 1308\u20131317 (2022).","journal-title":"Hep. Intl."},{"key":"60963_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s12072-022-10362-3","volume":"16","author":"YC Zhang","year":"2022","unstructured":"Zhang, Y. C. et al. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. Hep. Intl. 16, 835\u2013845. https:\/\/doi.org\/10.1007\/s12072-022-10362-3 (2022).","journal-title":"Hep. Intl."},{"key":"60963_CR7","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1016\/j.cgh.2021.06.042","volume":"20","author":"W Sohn","year":"2022","unstructured":"Sohn, W., Kwon, H. J., Chang, Y., Ryu, S. & Cho, Y. K. Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 20, e1135\u2013e1148. https:\/\/doi.org\/10.1016\/j.cgh.2021.06.042 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"60963_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jfma.2023.07.010","volume":"123","author":"KL Cheng","year":"2024","unstructured":"Cheng, K. L. et al. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease. J. Formos. Med. Association = Taiwan. yi zhi. 123, 36\u201344. https:\/\/doi.org\/10.1016\/j.jfma.2023.07.010 (2024).","journal-title":"J. Formos. Med. Association = Taiwan. yi zhi"},{"key":"60963_CR9","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/hep.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatol. (Baltimore Md. 78, 1966\u20131986. https:\/\/doi.org\/10.1097\/hep.0000000000000520 (2023).","journal-title":"Hepatol. (Baltimore Md."},{"key":"60963_CR10","doi-asserted-by":"crossref","unstructured":"Wan, K. S. et al. Prevalence of metabolic syndrome and metabolic dysfunction-associated fatty liver disease in Malaysia 2023: study protocol for a community-based nationwide cross-sectional survey. BMJ Open 13, e074432, (2023). https:\/\/doi.org\/10.1136\/bmjopen-2023-074432%J BMJ Open.","DOI":"10.1136\/bmjopen-2023-074432"},{"key":"60963_CR11","doi-asserted-by":"crossref","unstructured":"Chan, W. K. et al. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. Journal Gastroenterol. Hepatology (2022).","DOI":"10.1111\/jgh.15787"},{"key":"60963_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni, G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 1\u20137 (2006).","journal-title":"BMC Gastroenterol."},{"key":"60963_CR13","unstructured":"World Health Organization. Diagnosis and management of type 2 diabetes (HEARTS-D). (2020)."},{"key":"60963_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"World Health Organisation Expert Consultation","year":"2004","unstructured":"World Health Organisation Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157\u2013163 (2004).","journal-title":"Lancet"},{"key":"60963_CR15","unstructured":"World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment. (2000)."},{"key":"60963_CR16","unstructured":"Ministry of Health Malaysia. Clinical Practice Guidelines Management of Obesity 2nd edition. (2023). (2023)."},{"key":"60963_CR17","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1002\/jcsm.13099","volume":"13","author":"JY Seo","year":"2022","unstructured":"Seo, J. Y. et al. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J. cachexia sarcopenia muscle. 13, 2953\u20132960. https:\/\/doi.org\/10.1002\/jcsm.13099 (2022).","journal-title":"J. cachexia sarcopenia muscle"},{"key":"60963_CR18","unstructured":"Department of Statistics Malaysia. Household Income Survey Report 2022 (Putrajaya Malaysia, 2023)."},{"key":"60963_CR19","unstructured":"WHO Expert Consultation. Waist circumference and waist-hip ratio. Report of a WHO Expert Consultation. Geneva: World Health Organization. 8\u201311 (2008). (2008)."},{"key":"60963_CR20","unstructured":"Ministry of Health Malaysia. Clinical Practice Guidelines. Management of Hypertension 5th edition. (2018). (2018)."},{"key":"60963_CR21","unstructured":"Institute for Public Health (IPH). Technical report National Health and Morbidity Survey (NHMS) 2023: Non-Communicable Diseases and Healthcare Demand Malaysia. (2024)."},{"key":"60963_CR22","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120, 1640\u20131645 (2009).","journal-title":"Circulation"},{"key":"60963_CR23","unstructured":"Ministry of Health Malaysia. Clinical Practice Guidelines. Management of Dyslipidaemia 2023 6th edition. (2023)."},{"key":"60963_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino","year":"2008","unstructured":"D\u2019Agostino, R. B. et al. General Cardiovascular Risk Profile for Use in Primary Care. Circulation 117, 743\u2013753. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.699579 (2008).","journal-title":"Circulation"},{"key":"60963_CR25","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.3949\/ccjm.84.s2.04","volume":"84","author":"A Nowacki","year":"2017","unstructured":"Nowacki, A. Chi-square and Fisher\u2019s exact tests. Cleve. Clin. J. Med. 84, e20\u2013e25. https:\/\/doi.org\/10.3949\/ccjm.84.s2.04 (2017).","journal-title":"Cleve. Clin. J. Med."},{"key":"60963_CR26","first-page":"67","volume":"5","author":"K Suastika","year":"2012","unstructured":"Suastika, K., Dwipayana, P., Semadi, M. S. & Kuswardhani, R. T. J. G. T. Age is an important risk factor for type 2 diabetes mellitus and cardiovascular diseases. Glucose Tolerance. 5, 67\u201380 (2012).","journal-title":"Glucose Tolerance"},{"key":"60963_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12072-013-9510-8","volume":"8","author":"WK Chan","year":"2014","unstructured":"Chan, W. K. et al. Non-alcoholic fatty liver disease in a young multiracial Asian population: a worrying ethnic predilection in Malay and Indian males. Hep. Intl. 8, 121\u2013127. https:\/\/doi.org\/10.1007\/s12072-013-9510-8 (2014).","journal-title":"Hep. Intl."},{"key":"60963_CR28","first-page":"468","volume":"52","author":"V Mohan","year":"2004","unstructured":"Mohan, V. Why are Indians more prone to diabetes? J. Assoc. Phys. India. 52, 468\u2013474 (2004).","journal-title":"J. Assoc. Phys. India"},{"key":"60963_CR29","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s11892-012-0317-0","volume":"12","author":"JL Strom","year":"2012","unstructured":"Strom, J. L. & Egede, L. E. The impact of social support on outcomes in adult patients with type 2 diabetes: a systematic review. Curr. Diab. Rep. 12, 769\u2013781. https:\/\/doi.org\/10.1007\/s11892-012-0317-0 (2012).","journal-title":"Curr. Diab. Rep."},{"key":"60963_CR30","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00125-021-05496-2","volume":"64","author":"MT Schram","year":"2021","unstructured":"Schram, M. T., Assendelft, W. J. J., van Tilburg, T. G. & Dukers-Muijrers, N. Social networks and type 2 diabetes: a narrative review. Diabetologia 64, 1905\u20131916. https:\/\/doi.org\/10.1007\/s00125-021-05496-2 (2021).","journal-title":"Diabetologia"},{"key":"60963_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat. Reviews Gastroenterol. Hepatol. 19, 60\u201378. https:\/\/doi.org\/10.1038\/s41575-021-00523-4 (2022).","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"key":"60963_CR32","doi-asserted-by":"publisher","first-page":"17338","DOI":"10.1038\/s41598-023-44564-y","volume":"13","author":"KS Wan","year":"2023","unstructured":"Wan, K. S. et al. Baseline treatments and metabolic control of 288,913 type 2 diabetes patients in a 10-year retrospective cohort in Malaysia. Sci. Rep. 13, 17338. https:\/\/doi.org\/10.1038\/s41598-023-44564-y (2023).","journal-title":"Sci. Rep."},{"key":"60963_CR33","doi-asserted-by":"crossref","unstructured":"Huang, J. et al. MAFLD criteria guide the subtyping of patients with fatty liver disease. Risk Manage. Healthc. Policy, 491\u2013501 (2021).","DOI":"10.2147\/RMHP.S285880"},{"key":"60963_CR34","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.3350\/cmh.2022.0351","volume":"29","author":"P Konyn","year":"2023","unstructured":"Konyn, P., Ahmed, A. & Kim, D. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, S43\u2013s57. https:\/\/doi.org\/10.3350\/cmh.2022.0351 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"60963_CR35","unstructured":"Ministry of Health Malaysia. Clinical Practice Guidelines Management of Type 2 Diabetes Mellitus (6th Edition). (2020)."},{"key":"60963_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson, T. R., Acs, A., Ludwig, C. & Panton, U. H. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc. Diabetol. 17, 83. https:\/\/doi.org\/10.1186\/s12933-018-0728-6 (2018).","journal-title":"Cardiovasc. Diabetol."},{"key":"60963_CR37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hep. Intl. 14, 889\u2013919. https:\/\/doi.org\/10.1007\/s12072-020-10094-2 (2020).","journal-title":"Hep. Intl."},{"key":"60963_CR38","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cgh.2022.04.012","volume":"21","author":"H Park","year":"2023","unstructured":"Park, H. et al. Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy. Clin. Gastroenterol. Hepatol. 21, 1041\u20131049e1043. https:\/\/doi.org\/10.1016\/j.cgh.2022.04.012 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"60963_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.5009\/gnl210084","volume":"16","author":"Y Kim","year":"2022","unstructured":"Kim, Y. et al. Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. Gut Liver. 16, 290\u2013299. https:\/\/doi.org\/10.5009\/gnl210084 (2022).","journal-title":"Gut Liver"},{"key":"60963_CR40","doi-asserted-by":"publisher","first-page":"101485","DOI":"10.1016\/j.aohep.2024.101485","volume":"29","author":"KS Wan","year":"2024","unstructured":"Wan, K. S. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann. Hepatol. 29, 101485. https:\/\/doi.org\/10.1016\/j.aohep.2024.101485 (2024). Correspondence.","journal-title":"Ann. Hepatol."},{"key":"60963_CR41","doi-asserted-by":"publisher","unstructured":"Ellenberg, J. H. Selection bias in observational and experimental studies. 13, 557\u2013567, (1994). https:\/\/doi.org\/10.1002\/sim.4780130518","DOI":"10.1002\/sim.4780130518"},{"key":"60963_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan, W. K. et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J. Obes. metabolic syndrome. 32, 197\u2013213. https:\/\/doi.org\/10.7570\/jomes23052 (2023).","journal-title":"J. Obes. metabolic syndrome"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60963-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60963-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60963-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:46:48Z","timestamp":1791244008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60963-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60963"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60963-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Wah-Kheong Chan served as a consultant or advisory board member for Abbott, Roche, AbbVie, Boehringer Ingelheim, and Novo Nordisk and as a speaker for Abbott, Novo Nordisk, Echosens, Viatris, and Hisky Medical. Other authors do not have competing interests to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31041"}}